Trevi Therapeutics, Inc. (TRVI) earnings
TRVI earnings moved a median of -1.08% by the close. Quarterly and annual TRVI reports and results, each read against the price at its own news timestamp. Back to the TRVI overview →
27 measured TRVI earnings events.
Where these TRVI earnings landedvs 27 measured TRVI earnings reactions
| Middle 50% of TRVI earnings reactions | -5.02% to +1.42% |
|---|---|
| Median reaction (to close) | -1.08% |
| Measured reactions | 27 |
Point-in-time · zero look-ahead
Half of the 27 TRVI earnings events with a measured close landed between -5.02% and +1.42%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Trevi Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.69% | -3.89% | |
| Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | -3.69% | -3.89% | |
| Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 | Press release | -2.22% | -1.30% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.14% | +0.85% | |
| Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | +0.14% | +0.85% | |
| Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 | Press release | +0.33% | +1.10% | |
| Form 10-K Trevi Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -6.49% | -9.87% | |
| Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 | Press release | +0.09% | +0.09% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.69% | +2.91% | |
| Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | -0.69% | +2.91% | |
| Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 | Press release | +0.54% | -1.08% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -6.62% | -7.43% | |
| Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | -6.62% | -7.43% | |
| Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 | Press release | +2.17% | +1.30% | |
| Form 10-K Trevi Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.15% | -2.44% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.25% | -6.15% | |
| Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | +2.25% | -6.15% | |
| Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 | Press release | -1.97% | -3.13% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +1.42% | |
| Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance | Press release | +0.00% | +1.42% | |
| Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 | Press release | +0.00% | -2.52% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.15% | +1.54% | |
| Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates | Press release | +2.15% | +1.54% | |
| Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 | Press release | +0.00% | +4.15% | |
| Form 10-K Trevi Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.17% | +6.63% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.14% | -7.09% | |
| Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update | Press release | -0.14% | -7.09% |
Keep exploring
More TRVI: analyst actions → · SEC filings → · TRVI overview →